Methodology: 2.5/5
Usefulness: 2/5

Ramakrishnan S, et al. Lancet Respir Med. 2021 Apr 9:S2213-2600(21)00160-0.

Question and Methods: Is inhaled budesonide an effective treatment for patients with mild early symptoms of COVID-19? A randomized, open-label clinical trial of community patients with suspected COVID-19. 
Findings: Reduction in composite outcome of visits to urgent care, emergency department, or hospitalization in budesonide versus usual care (ARR 0.123; 95% CI 0.033-0.213, p=0.009). 
Limitations: Unequal outcomes in composite outcome, open label design, and small sample size due to early trial stoppage. 

Interpretation: Based on the limitations, this study – while showing a signal – does not provide enough evidence to warrant routine use of inhaled glucocorticoids for early COVID-19 disease.

By: Dr.  Hashim Kareemi

For more information on COVID-19 please go to this link.


  • Hans Rosenberg

    Dr. Rosenberg is an emergency physician at the Ottawa Hospital, assistant professor at the University of Ottawa, and Director of the Digital Scholarship and Knowledge Dissemination Program.

    View all posts